Threat Agnostic Diagnostics

The following awards were made in support of the Threat Agnostic Diagnostics initiative (RPP-26-09-AgDx), which will support the advanced development, clinical evaluation, and FDA clearance of metagenomic Next-Generation Sequencing (mNGS)-based diagnostic assays focused on viral and bacterial pathogens. The product sought is a highly flexible, rapidly adaptable system that identifies known viral and bacterial pathogens (e.g., detection/identification of all known viral and bacterial pathogens in a respiratory specimen) and can quickly be adapted with changes to only databases or software to detect new viral and bacterial pathogens during an event or public health emergency. Both laboratory and point-of-care tests are sought for use on existing mNGS-based sequencing platforms or on platforms already in development.